PT - JOURNAL ARTICLE AU - Ling Ong, Jasmine Chiat AU - Michael, Chen AU - Ng, Ning AU - Elangovan, Kabilan AU - Ting Tan, Nichole Yue AU - Jin, Liyuan AU - Xie, Qihuang AU - Wei Ting, Daniel Shu AU - Rodriguez-Monguio, Rosa AU - Bates, David W. AU - Liu, Nan TI - Generative AI and Large Language Models in Reducing Medication Related Harm and Adverse Drug Events – A Scoping Review AID - 10.1101/2024.09.13.24313606 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.13.24313606 4099 - http://medrxiv.org/content/early/2024/09/14/2024.09.13.24313606.short 4100 - http://medrxiv.org/content/early/2024/09/14/2024.09.13.24313606.full AB - Background Medication-related harm has a significant impact on global healthcare costs and patient outcomes, accounting for deaths in 4.3 per 1000 patients. Generative artificial intelligence (GenAI) has emerged as a promising tool in mitigating risks of medication-related harm. In particular, large language models (LLMs) and well-developed generative adversarial networks (GANs) showing promise for healthcare related tasks. This review aims to explore the scope and effectiveness of generative AI in reducing medication-related harm, identifying existing development and challenges in research.Methods We searched for peer reviewed articles in PubMed, Web of Science, Embase, and Scopus for literature published from January 2012 to February 2024. We included studies focusing on the development or application of generative AI in mitigating risk for medication-related harm during the entire medication use process. We excluded studies using traditional AI methods only, those unrelated to healthcare settings, or concerning non-prescribed medication uses such as supplements. Extracted variables included study characteristics, AI model specifics and performance, application settings, and any patient outcome evaluated.Findings A total of 2203 articles were identified, and 14 met the criteria for inclusion into final review. We found that generative AI and large language models were used in a few key applications: drug-drug interaction identification and prediction; clinical decision support and pharmacovigilance. While the performance and utility of these models varied, they generally showed promise in areas like early identification and classification of adverse drug events and support in decision-making for medication management. However, no studies tested these models prospectively, suggesting a need for further investigation into the integration and real-world application of generative AI tools to improve patient safety and healthcare outcomes effectively.Interpretation Generative AI shows promise in mitigating medication-related harms, but there are gaps in research rigor and ethical considerations. Future research should focus on creation of high-quality, task-specific benchmarking datasets for medication safety and real-world implementation outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Duke-NUS Medical SchoolAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors